Manawa Energy Q2 Operating Report & Market Guidance Update

MKTUPDTE
Tue, Oct 18 2022 08:34 am

Electricity generator and renewables developer Manawa Energy ('Manawa') has revised its forecast earnings for the 12 months to 31 March 2023.

Manawa had previously issued guidance that EBITDAF for FY23 was expected to be within a range of $140m-$160m. However, it is now expecting EBITDAF for FY23 to be within a range of $127.5m-$140m.

FY23 EBITDAF includes new generation development expenditure of $6m to $8m.

The revised guidance is underpinned by the following factors:
• A challenging first half, with an initial period of high prices and low inflows, followed by a period of strong inflows and low prices.
• Increased operational expenditure for activity in relation to new developments, including the acquisition of renewable generation options as projects are progressed faster than anticipated (more details will be provided at the interim results announcement next month).
• A significant uplift in forward prices from calendar year 2024, driving strategic water storage decisions that mitigate risks.
• Repairs and maintenance driven by recent significant weather-related events (particularly across Q2) that require an urgent response.

Manawa’s revised guidance assumes:
• Wholesale prices remain materially in line with the current ASX forward curve.
• Manawa generation volumes in the second half of the year will be ~830 GWh.
• Average hydrological conditions occur for the remainder of the financial year.
• No material adverse events

Note that the range of Manawa's expected capital expenditure in FY23 remains unchanged at $45m-$55m.


Investor enquiries:
Phil Wiltshire
General Manager Corporate Services
0275 826600
[email protected]


Media enquiries:
Paul Ford
Head of Corporate Relations
021 809589
[email protected]


Announcement PDF


Markets News

Auckland Airport dominates volumes; NZX dips 0.61%
Markets Market Close

Auckland Airport dominates volumes; NZX dips 0.61%

The S&P/ASX 200 has recovered from the US's so-called "Liberation Day".

Markets

Pacific Edge upbeat about latest move for new test

The median price for Cxbladder Triage Plus is US$1,018.44.

Pacific Edge upbeat about latest move for new test